{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:42:19Z","timestamp":1787870539534,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95758-5","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:05:09Z","timestamp":1743786309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The inflammation burden index can predict the cardiac injury following antitumour therapy in lung cancer patients with diabetes"],"prefix":"10.1038","volume":"15","author":[{"given":"Yumin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"95758_CR1","doi-asserted-by":"publisher","unstructured":"Vi\u00f1as-Mendieta, A. E., Gallardo-Grajeda, A. & L\u00f3pez-Fern\u00e1ndez, T. Cardio-oncology: chances and challenges. Basic. Res. Cardiol. Published Online September 30 https:\/\/doi.org\/10.1007\/s00395-024-01080-y (2024).","DOI":"10.1007\/s00395-024-01080-y"},{"issue":"41","key":"95758_CR2","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R. et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur. Heart J. 43(41), 4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244 (2022).","journal-title":"Eur. Heart J."},{"issue":"8","key":"95758_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann, J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat. Rev. Cardiol. 17(8), 474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1 (2020).","journal-title":"Nat. Rev. Cardiol."},{"issue":"41","key":"95758_CR4","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1093\/eurheartj\/ehae637","volume":"45","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2024","unstructured":"L\u00f3pez-Fern\u00e1ndez, T. et al. Breast cancer and cardiovascular health. Eur. Heart J. 45(41), 4366\u20134382. https:\/\/doi.org\/10.1093\/eurheartj\/ehae637 (2024).","journal-title":"Eur. Heart J."},{"issue":"5","key":"95758_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11912-023-01387-4","volume":"25","author":"N Yegya-Raman","year":"2023","unstructured":"Yegya-Raman, N., Berlin, E., Feigenberg, S. J., Ky, B. & Sun, L. Cardiovascular toxicity and risk mitigation with lung cancer treatment. Curr. Oncol. Rep. 25(5), 433\u2013444. https:\/\/doi.org\/10.1007\/s11912-023-01387-4 (2023).","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"95758_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Global Burden of Disease 2019 Cancer Collaboration","year":"2022","unstructured":"Global Burden of Disease 2019 Cancer Collaboration et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol. 8(3), 420\u2013444. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6987 (2022).","journal-title":"JAMA Oncol."},{"issue":"18","key":"95758_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J L\u00f3pez-Send\u00f3n","year":"2020","unstructured":"L\u00f3pez-Send\u00f3n, J. et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry. Eur. Heart J. 41(18), 1720\u20131729. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006 (2020).","journal-title":"Eur. Heart J."},{"issue":"1","key":"95758_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12935-022-02760-2","volume":"22","author":"XT Zhang","year":"2022","unstructured":"Zhang, X. T., Ge, N., Xiang, Z. J. & Liu, T. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: A systematic review and meta-analysis. Cancer Cell Int. 22(1), 363. https:\/\/doi.org\/10.1186\/s12935-022-02760-2 (2022).","journal-title":"Cancer Cell Int."},{"key":"95758_CR9","doi-asserted-by":"publisher","first-page":"1298345","DOI":"10.3389\/fendo.2023.1298345","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Guan, M., Wang, R. & Wang, X. Relationship between advanced lung cancer inflammation index and long-term all-cause, cardiovascular, and cancer mortality among type 2 diabetes mellitus patients: NHANES, 1999\u20132018. Front. Endocrinol. (Lausanne) 14, 1298345. https:\/\/doi.org\/10.3389\/fendo.2023.1298345 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"95758_CR10","doi-asserted-by":"publisher","first-page":"117843","DOI":"10.1016\/j.lfs.2020.117843","volume":"255","author":"S L\u2019Abbate","year":"2020","unstructured":"L\u2019Abbate, S., Russo, I. & Kusmic, C. The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know. Life Sci. 255, 117843. https:\/\/doi.org\/10.1016\/j.lfs.2020.117843 (2020).","journal-title":"Life Sci."},{"issue":"11","key":"95758_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon, A. R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology study group of the heart failure association of the European society of cardiology in collaboration with the international Cardio-Oncology society. Eur. J. Heart Fail. 22(11), 1945\u20131960. https:\/\/doi.org\/10.1002\/ejhf.1920 (2020).","journal-title":"Eur. J. Heart Fail."},{"issue":"21","key":"95758_CR12","doi-asserted-by":"publisher","first-page":"e029574","DOI":"10.1161\/JAHA.123.029574","volume":"12","author":"G Murtagh","year":"2023","unstructured":"Murtagh, G. et al. Circulating cardiovascular biomarkers in cancer therapeutics-related cardiotoxicity: Review of critical challenges, solutions, and future directions. J. Am. Heart Assoc. 12(21), e029574. https:\/\/doi.org\/10.1161\/JAHA.123.029574 (2023).","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"95758_CR13","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.clnu.2022.04.019","volume":"41","author":"H Xie","year":"2022","unstructured":"Xie, H. et al. Inflammatory burden as a prognostic biomarker for cancer. Clin. Nutr. 41(6), 1236\u20131243. https:\/\/doi.org\/10.1016\/j.clnu.2022.04.019 (2022).","journal-title":"Clin. Nutr."},{"issue":"2","key":"95758_CR14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/jcsm.13199","volume":"14","author":"H Xie","year":"2023","unstructured":"Xie, H. et al. The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer. J. Cachexia Sarcopenia Muscle. 14(2), 869\u2013878. https:\/\/doi.org\/10.1002\/jcsm.13199 (2023).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"1","key":"95758_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-024-02173-7","volume":"23","author":"XZ Hou","year":"2024","unstructured":"Hou, X. Z. et al. Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study. Cardiovasc. Diabetol. 23(1), 86. https:\/\/doi.org\/10.1186\/s12933-024-02173-7 (2024).","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"95758_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino, F. et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41(2), 255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486 (2020).","journal-title":"Eur. Heart J."},{"issue":"1","key":"95758_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-019-0982-2","volume":"19","author":"J Alizargar","year":"2020","unstructured":"Alizargar, J., Bai, C. H., Hsieh, N. C. & Wu, S. F. V. Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients. Cardiovasc. Diabetol. 19(1), 8. https:\/\/doi.org\/10.1186\/s12933-019-0982-2 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"95758_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathmechdis-032221-115501","volume":"17","author":"L Maiorino","year":"2022","unstructured":"Maiorino, L., Da\u00dfler-Plenker, J., Sun, L. & Egeblad, M. Innate immunity and cancer pathophysiology. Annu. Rev. Pathol. 17, 425\u2013457. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-032221-115501 (2022).","journal-title":"Annu. Rev. Pathol."},{"issue":"6","key":"95758_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41569-019-0326-7","volume":"17","author":"C Silvestre-Roig","year":"2020","unstructured":"Silvestre-Roig, C., Braster, Q., Ortega-Gomez, A. & Soehnlein, O. Neutrophils as regulators of cardiovascular inflammation. Nat. Rev. Cardiol. 17(6), 327\u2013340. https:\/\/doi.org\/10.1038\/s41569-019-0326-7 (2020).","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"95758_CR20","doi-asserted-by":"publisher","first-page":"e6837","DOI":"10.1002\/cam4.6837","volume":"13","author":"C Cai","year":"2024","unstructured":"Cai, C. et al. An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study. Cancer Med. 13(3), e6837. https:\/\/doi.org\/10.1002\/cam4.6837 (2024).","journal-title":"Cancer Med."},{"key":"95758_CR21","doi-asserted-by":"publisher","first-page":"1321622","DOI":"10.3389\/fendo.2024.1321622","volume":"15","author":"X Wu","year":"2024","unstructured":"Wu, X. et al. Association between triglyceride glucose index and breast cancer in 142,184 Chinese adults: findings from the REACTION study. Front. Endocrinol. (Lausanne) 15, 1321622. https:\/\/doi.org\/10.3389\/fendo.2024.1321622 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"95758_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-024-02244-9","volume":"23","author":"C Cui","year":"2024","unstructured":"Cui, C. et al. Joint association of TyG index and high sensitivity C-reactive protein with cardiovascular disease: A National cohort study. Cardiovasc. Diabetol. 23(1), 156. https:\/\/doi.org\/10.1186\/s12933-024-02244-9 (2024).","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"95758_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-022-01548-y","volume":"21","author":"J Zhao","year":"2022","unstructured":"Zhao, J. et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc. Diabetol. 21(1), 123. https:\/\/doi.org\/10.1186\/s12933-022-01548-y (2022).","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"95758_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-023-02115-9","volume":"23","author":"K Dang","year":"2024","unstructured":"Dang, K. et al. The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003\u20132018. Cardiovasc. Diabetol. 23(1), 8. https:\/\/doi.org\/10.1186\/s12933-023-02115-9 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"95758_CR25","doi-asserted-by":"publisher","first-page":"111727","DOI":"10.1016\/j.diabres.2024.111727","volume":"213","author":"LLF Hoes","year":"2024","unstructured":"Hoes, L. L. F. et al. Relationship of neutrophil-to-lymphocyte ratio, in addition to C-reactive protein, with cardiovascular events in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 213, 111727. https:\/\/doi.org\/10.1016\/j.diabres.2024.111727 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"19","key":"95758_CR26","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.3390\/cells11193001","volume":"11","author":"H Li","year":"2022","unstructured":"Li, H. et al. Macrophages, chronic inflammation, and insulin resistance. Cells 11(19), 3001. https:\/\/doi.org\/10.3390\/cells11193001 (2022).","journal-title":"Cells"},{"issue":"5","key":"95758_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"21","author":"A Poznyak","year":"2020","unstructured":"Poznyak, A. et al. The diabetes mellitus-atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int. J. Mol. Sci. 21(5), 1835. https:\/\/doi.org\/10.3390\/ijms21051835 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"95758_CR28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/heartjnl-2022-322230","volume":"109","author":"J Banchs","year":"2023","unstructured":"Banchs, J. & Lech, T. Cardiovascular phenotypes and incident cardiovascular events in people with previous cancer. Heart 109(13), 974\u2013976. https:\/\/doi.org\/10.1136\/heartjnl-2022-322230 (2023).","journal-title":"Heart"},{"issue":"5","key":"95758_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tem.2024.02.003","volume":"35","author":"M Mashayekhi","year":"2024","unstructured":"Mashayekhi, M., Safa, B. I., Gonzalez, M. S. C., Kim, S. F. & Echouffo-Tcheugui, J. B. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors. Trends Endocrinol. Metab. 35(5), 425\u2013438. https:\/\/doi.org\/10.1016\/j.tem.2024.02.003 (2024).","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"95758_CR30","doi-asserted-by":"publisher","first-page":"eadj4686","DOI":"10.1126\/sciadv.adj4686","volume":"10","author":"G Ursino","year":"2024","unstructured":"Ursino, G. et al. S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects. Sci. Adv. 10(1), eadj4686. https:\/\/doi.org\/10.1126\/sciadv.adj4686 (2024).","journal-title":"Sci. Adv."},{"key":"95758_CR31","doi-asserted-by":"publisher","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","volume":"15","author":"W Jo","year":"2024","unstructured":"Jo, W., Won, T., Daoud, A. & \u010cih\u00e1kov\u00e1, D. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events. Front. Immunol. 15, 1340373. https:\/\/doi.org\/10.3389\/fimmu.2024.1340373 (2024).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95758-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95758-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95758-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:53:07Z","timestamp":1744285987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95758-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95758"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95758-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Investigational Review Board of Xuzhou Medical University Affiliated Hospital (Approval number XYFY2024-KL156). The requirement for signed written consent was waived owing to no risk to the patient in accordance with the relevant regulatory guidelines of the Investigational Review Board of the Affiliated Hospital of Xuzhou Medical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"11291"}}